Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission

Chronic myeloid leukemia (CML) is a hematological cancer, characterized by a reciprocal chromosomal translocation between chromosomes 9 and 22 [t(9;22)], producing the Bcr-Abl oncogene. Tyrosine kinase inhibitors (TKIs) represent the standard of care for CML patients and exert a dual mode of action:...

Descripción completa

Detalles Bibliográficos
Autores principales: Hughes, Amy, Yong, Agnes S. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5402174/
https://www.ncbi.nlm.nih.gov/pubmed/28484463
http://dx.doi.org/10.3389/fimmu.2017.00469

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5402174/
https://www.ncbi.nlm.nih.gov/pubmed/28484463
http://dx.doi.org/10.3389/fimmu.2017.00469

Ejemplares similares